S. Uhlig et al., EFFECT OF URODILATIN ON PLATELET-ACTIVATING FACTOR-INDUCED BRONCHOCONSTRICTION, VASOCONSTRICTION AND EDEMA FORMATION IN ISOLATED RAT LUNG, Naunyn-Schmiedeberg's archives of pharmacology, 354(5), 1996, pp. 684-688
In the isolated perfused rat lung, perfusion with platelet-activating
factor causes bronchoconstriction, vasoconstriction and edema formatio
n. The bronchoconstriction and vasoconstriction are largely mediated b
y thromboxane, whereas the edema formation is due to enhanced vascular
permeability unrelated to eicosanoids. Since natriuretic peptides are
known to relax smooth muscle and were suggested to attenuate enhanced
vascular permeability, we investigated the effect of urodilatin on th
e PAF-induced alterations in lung function. Pretreatment with urodilat
in (0.25 mu M or 0.75 mu M) reduced the PAF-induced increase in airway
and vascular resistance by approximately 50%. Urodilatin pretreatment
, however, was completely ineffective against the PAF-induced increase
in weight gain and in vascular permeability, as assessed by the vascu
lar filtration coefficient. Furthermore, urodilatin failed to affect t
he release of thromboxane into the perfusate in PAF-exposed lungs. Thu
s, urodilatin relaxes airway and vascular smooth muscle, but fails to
reduce edema formation in PAF-perfused rat lungs.